AG-7088 Pfizer

Area of Science:

• Pharmacology
• Virology
• Drug Development

Background:

• Human rhinovirus (HRV) is a common cause of the common cold.
• Existing treatments for the common cold are limited.
• HRV 3C proteinase is a key enzyme for viral replication.

Purpose of the Study:

• To develop novel inhibitors of the human rhinovirus 3C proteinase.
• To evaluate the efficacy of AG-7088, a peptide aldehyde, for treating the common cold.

Main Methods:

• Development of AG-7088, a derivative of AG-6084, with improved pharmacological properties.
• Modification of the molecular structure to enhance cell membrane permeability and enzyme inhibition.
• Phase II efficacy study in healthy patients infected with HRV.
• Initiation of a large, double-blind, placebo-controlled trial in the US.

Main Results:

• AG-7088 demonstrated potent inhibition of HRV 3C proteinase.
• Structural modifications led to improved antiviral properties and cell membrane permeability.
• Phase II trials showed efficacy in patients with cold symptoms.

Conclusions:

• AG-7088 is a promising candidate for the treatment of the common cold.
• Further clinical trials (Phase III) are anticipated.
• The development of HRV 3C proteinase inhibitors represents a significant advancement in antiviral therapy.